Skin CA Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

HPV trx

A

imiquimod

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

BRAF inhibition

A

vemurafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

retinal pigment epithelium detachment

A

trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Genetic testing

A

vemurafenib trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Caution in autoimm disease, cardiac disease, depression, infection

A

interferon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

dermatitic, including toxic epidermal necrolysis

A

ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

iritis, retinal vein occlusion, uvetis

A

vemurafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Photosensitivity

A

imiquimod vemurafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Blood dyscrasia

A

sorafenib trametinib interferon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

indiscriminant T cell activation

A

ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

blocks hedgehog via adenosine R

A

imiquimod

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

intrauterine fetal death

A

vismodegib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LV dysf

A

trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

decreased mental status, corticol blindness ataxia

A

aldesleukin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diarrhea

A

trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

cutaneous SCC arises in 1/4 of patients

A

vemurafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Rash

A

vemurafenib trametinib imiquimod sorafenib ipilimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PULM

A

aldesleukin interferon trametinib

17
Q

Secondary tumors

A

vemurafenib

18
Q

Hepatic toxicity

A

aldesleukin interferon sorafenib vemurafenib

18
Q

Pneumonia and pulmonary infiltrates

A

interferon

18
Q

QT prolongation

A

vemurafenib

19
Q

BCC

A

imiquimod vismodegib

20
Q

CV

A

vemurafenib trametinib interferon aldesleukin

20
Q

Pulm, GI, and brain bleeding

A

sorafenib

21
Q

Binds IL2 => expands anti-tumor lymphocyte population

A

aldesleukin

23
Q

Category D

A

sorafenib vemurafenib trametinib vismodegib

24
Q

male-mediated teratogenicity

A

vismodegib

25
Q

Endocrinopathies

A

ipilimumab

26
Q

RAF kinase = target

A

sorafenib

27
Q

SJS

A

vemurafenib

29
Q

Category C

A

aldesleukin interferon imiquimod ipilimumab

31
Q

Must have normal CV, pulm, renal function

A

aldesleukin

32
Q

contraception needed + no blood donation x7mo

A

vismodegib

34
Q

hypotension, SVT

A

aldesleukin

36
Q

Not for organ transplant recipients

A

aldesleukin

37
Q

TH1, TNF-alpha, IL

A

imiquimod

38
Q

MEK = target

A

trametinib

39
Q

BBW: Guillain-Barre, myasthenia gravis, pregnancy

A

ipilimumab

40
Q

Renal capillary leak syndrome

A

aldesleukin

41
Q

CTLA4 antigen

A

ipilimumab

42
Q

Suicidal ideation

A

interferon

43
Q

“eye”

A

vemurafenib trametinib